HHS Public Access

Author manuscript
Schizophr Res. Author manuscript; available in PMC 2019 April 01.
Author Manuscript

Published in final edited form as:

Schizophr Res. 2018 April ; 194: 62–69. doi:10.1016/j.schres.2017.03.047.

Minimal Effects of Prolonged Smoking Abstinence or

Resumption on Cognitive Performance Challenge the “Self-
Medication” Hypothesis in Schizophrenia
Douglas L Boggs, Pharm.D., M.S.a,b, Toral S. Surti, M.D., Ph.D.a,b, Irina Esterlis, Ph.D.a,b,c,
Brian Pittman, M.S.b,c, Kelly Cosgrove, Ph.D.a,b,c, R. Andrew Sewell, M.D.a,b,c, Mohini
Ranganathan, M.D.a,b,c, and Deepak Cyril D’Souza, M.D.a,b,c
Author Manuscript

aPsychiatry Service, VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT,
06516 USA
bDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
cAbraham Ribicoff Research Facilities, Connecticut Mental Health Center, 34 Park Street, New
Haven, CT, 06519 USA

Abstract
One prominent, long-standing view is that individuals with schizophrenia smoke cigarettes more
than the general population to “self-medicate” cognitive deficits and other symptoms. This study
tested the self-medication hypothesis by examining the effects of smoking abstinence and
resumption on cognition in patients with schizophrenia. Nicotine-dependent smokers with
Author Manuscript

schizophrenia (n=26) were trained on a cognitive battery and then hospitalized to achieve and
maintain confirmed abstinence from smoking for ~1 week. Cognition was tested while smoking as
usual (baseline), one day after smoking cessation (early abstinence), ~1 week later (extended
abstinence), and within ~3 weeks of resuming smoking (resumption). The test battery included
measures of processing speed, attention, conflict resolution, verbal memory, working memory,
verbal fluency, and executive function to evaluate multiple cognitive domains affected by
schizophrenia. Positive and negative symptoms of schizophrenia, depressive symptoms, and
dyskinesia were also measured at baseline and after prolonged abstinence. There were no
significant changes in global cognitive test performance with smoking cessation, abstinence, or
resumption. There were small decreases in a measure of processing speed and delayed verbal
recall with abstinence, but these findings failed to survive adjustments for multiple comparisons.
Surprisingly, in this within subject “On- Off—Off-On” design, there were no significant effects of
Author Manuscript

early or prolonged abstinence from smoking on cognitive and behavioral measures in smokers
with schizophrenia. The results of this study challenge the widely held “self-medication”

Corresponding Author: Deepak Cyril D’Souza, M.D., Psychiatry Service 116A, VA Connecticut Healthcare System, 950 Campbell
Avenue, West Haven, CT 06516, Phone: (203) 932-5711 x 2594 Fax: (203) 937-4860, deepak.dsouza@yale.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
CONFLICTS OF INTEREST: none of the authors report conflict of interest for this study.
 Boggs et al. Page 2

hypothesis of smoking and schizophrenia, question the extent of pro-cognitive effects of smoking
Author Manuscript

and nicotine in schizophrenia, and support encouraging smoking cessation in schizophrenia.

Keywords
schizophrenia; cognition; smoking; nicotine; tobacco; withdrawal; abstinence

1. INTRODUCTION
The rates of tobacco use and nicotine addiction in schizophrenia are extremely high, with a
recent study showing 70–80% prevalence (Hartz et al., 2014) and some studies showing near
90% prevalence (de Leon and Diaz, 2005; Hughes et al., 1986). Smokers with schizophrenia
have reduced smoking cessation rates, extract more nicotine per cigarette and smoke higher
Author Manuscript

numbers of stronger cigarettes, all indicators of greater nicotine dependence than other
smokers (Dalack et al., 1998; de Leon and Diaz, 2005; Hughes et al., 1986). One widely-
held theory about smoking behavior in schizophrenia is the “self-medication hypothesis”
according to which patients smoke tobacco to attenuate positive, negative, depressive or
cognitive symptoms or antipsychotic medication side effects (Kumari and Postma, 2005;
Leonard et al., 2007; Wing et al., 2012). Nicotine or tobacco smoking, however, does not
seem to improve positive psychotic symptoms (Smith et al., 2002), and psychotic symptoms
do not worsen during nicotine withdrawal (Dalack et al., 1999; Yang et al., 2002). More
research interest has been focused on the effects of nicotine on the very disabling negative
symptoms and cognitive deficits of schizophrenia (Smucny et al., 2016; Yee et al., 2015), but
the evidence has been mixed.

Some literature suggests that there are schizophrenia-specific beneficial effects of nicotine
Author Manuscript

and nicotinic cholinergic agents on some cognitive deficits, electrophysiologic measures of

early information processing, oculomotor dysfunction and affect (Dépatie et al., 2002;
George et al., 2002; Olincy et al., 2000). Studies of nicotine administration and tobacco
smoking on cognitive test performance in schizophrenia have yielded conflicting results with
some reporting improvements in processing speed, working memory and executive function
while others found no significant improvements (Boggs et al., 2013; Hahn et al., 2013;
Harris et al., 2004; Smith et al., 2002; Wing et al., 2011). Some of this variability may be
due to methodological differences or subject characteristics in these studies. Studies of
acute, overnight, short-term (hours) withdrawal followed by resumption of smoking suggest
that nicotine improves visuospatial working memory in schizophrenia (George et al., 2002;
Sacco et al., 2005). Although several studies suggest that nicotine acutely improves attention
in schizophrenia, whether it improves other cognitive domains, overall cognition, or confers
Author Manuscript

long-term benefits is unclear (Boggs et al., 2014). Furthermore, though other nicotinic
acetylcholine receptor (nAChR) ligands have been pursued for treating the cognitive deficits
of schizophrenia, unfortunately standardized cognitive test batteries have failed to capture
consistent improvements from these drugs (Boggs et al., 2014). If the self-medication
hypothesis explained the increased smoking in schizophrenia, we would expect smokers
with schizophrenia to have more cognitive gains from smoking and greater cognitive costs of
smoking cessation than otherwise healthy smokers. In addition, the effects of smoking

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 3

cessation and withdrawal on cognition do not seem specific to schizophrenia, which further
Author Manuscript

questions the self-medication hypothesis of smoking. Instead, smoking cessation and

withdrawal from nicotine has been reported to precipitate neurocognitive deficits, such as
impaired working memory, in healthy smokers without psychiatric illness (Mendrek et al.,
2006; Patterson et al., 2010), and, nicotine withdrawal or smoking resumption does not
result in specific changes in attention in schizophrenia beyond the healthy smokers, as would
be predicted by the self-medication hypothesis (AhnAllen et al., 2015; Hahn et al., 2013)
However, the benefits of nicotine use for global cognition in schizophrenia during long-term
abstinence, rather than acute withdrawal, is not well known. To our knowledge, there are no
studies in smokers with schizophrenia assessing global cognitive test performance following
a longer period of confirmed abstinence- a period that extends beyond the acute withdrawal
stage. We studied the impact of confirmed early (1 day) and extended abstinence (~1 week)
from smoking on cognitive test performance across several cognitive domains in smokers
Author Manuscript

with schizophrenia. Furthermore, we investigated the effects of smoking resumption on

cognitive test performance in the same subjects. Demonstrating that early and extended
abstinence impairs, while resumption of smoking improves, global cognitive test
performance might explain why smokers with schizophrenia find it harder to quit and why
they are more likely to resume smoking. Given the widely held “self-medication” hypothesis
of smoking and schizophrenia, we also studied the effects of smoking cessation on the core
symptoms of schizophrenia, depression symptoms and dyskinesia. Finally, we studied the
effects of smoking cessation on nicotine craving and nicotine withdrawal. We hypothesized
early and extended smoking abstinence would be responsible for decreased global cognitive
performance that would reverse during smoking resumption.

2. METHODS
Author Manuscript

2.1 Subjects
Data reported here were obtained from subjects who participated in a single- photon
emission computerized tomography (SPECT) imaging study of β2*-nAChR availability in
schizophrenia (D’Souza et al., 2012; Esterlis et al., 2014) that required confirmed inpatient
abstinence from tobacco smoking for ~1 week (mean admission 5.8 days, SD 0.6, range 5–7
days, with reason for variability being coordinating participants’ scheduling with schedule of
imaging procedures reported elsewhere). While some of the methods and the results of
β2*nAChR availability are reported elsewhere (D’Souza et al., 2012; Esterlis et al., 2014),
the principal findings reported here have not been published elsewhere. Eligibility criteria
included: 1) age 18–70 years old; 2) schizophrenia diagnosis confirmed based on DSM-IV
criteria, clinical records, clinician input, and use of the Structured Clinical Interview for
DSM-IV (SCID) (First et al., 1997); 3) cigarette smokers who smoked at least 10 cigarettes
Author Manuscript

a day, verified at baseline by a plasma cotinine level >150 ng/ml, urine cotinine level > 100
ng/ml (NicAlert™ by Nymox Pharmaceutical Corporation), and carbon monoxide (CO)
level > 11 ppm (MicroDirect-Micro CO meter (Cat. No. MC02). Exclusion criteria included
1) any other current axis I diagnosis besides schizophrenia; 2) diagnosis of substance abuse
in the past month or substance dependence in the previous 6 months (excluding nicotine and
caffeine); 3) treatment with selective serotonin re-uptake inhibitors and/or tetra/tricyclic
antidepressants; 4) psychiatric or medical instability. Lifetime history of and/or current

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 4

substance use disorders were ascertained by psychiatric interview, chart review, SCID-I/P,
Author Manuscript

30-day Timeline Followback, and urine toxicology.

2.2 Study Procedures

2.2.1 Regulatory Approvals and Consent Process—Both the Yale University and
VA Connecticut Healthcare System Institutional Review Boards approved this study. All
subjects signed informed consent after the study was explained to them in detail as described
elsewhere (D’Souza et al., 2012; Esterlis et al., 2014).

2.2.2 Screening—Methods for some aspects of this study have been reported previously
(D’Souza et al., 2012; Esterlis et al., 2014). Subjects who met study criteria had screening
assessments conducted including demographic data, clinical history, clinical ratings
including the Positive and Negative Symptom Scale (PANSS) (Kay et al., 1987), Scale for
Author Manuscript

the Assessment of Negative Symptoms (SANS) (Andreasen, 1982), Montgomery-Asberg

Depression Scale (MADRS) (Montgomery, 1979), Abnormal Involuntary Movement Scale
(AIMS) (Guy, 1976b), cigarette usage, and degree of nicotine dependence measured by the
Fagerström Test for Nicotine Dependence (FTND) (Heatherton et al., 1991).

2.2.3 Smoking cessation—Eligible smokers with schizophrenia were hospitalized on a

smoke-free research unit to achieve and maintain abstinence from smoking for at least 5
days. Subjects were not allowed to receive any drugs that could facilitate smoking
abstinence, including varenicline, bupropion, and nicotine replacement. Trained research
staff counseled subjects daily to cope with withdrawal symptoms. Counseling was paired
with contingency management: the latter has been shown to reduce cigarette smoking in
smokers with schizophrenia in short-term studies (D’Souza et al., 2012; Roll et al., 1998;
Tidey et al., 1999; Tidey et al., 2011). Subjects were paid $25 for the first day of inpatient
Author Manuscript

abstinence, and payments were escalated by $25 for every inpatient day. Thus, if subjects
were able to complete the entire inpatient abstinence period of at least 5 days, they were
eligible to receive up to $375. Abstinence from smoking or any other nicotine products was
confirmed by daily breath CO monitoring (cutoff < 8ppm) and urinary cotinine (cutoff < 50
ng/ml) [NicAlert, (Nymox)] (see Supplemental Table 1 for interpretation of assays). In
addition, plasma cotinine was assayed while smoking as usual and after ~1 week of
abstinence. Finally, subjects were aware that failure to abstain triggered discharge from the
study.

2.2.4 Cognitive Test Battery—Multiple domains of cognitive function were tested using
a battery of tests that have been shown to be sensitive to nicotine administration, withdrawal,
and or abstinence in smokers with and without schizophrenia reviewed in (Boggs et al., 2014)
Author Manuscript

and normal controls reviewed in (Heishman et al., 2010; Heishman et al., 1993). Furthermore,
the cognitive domains tested, executive functioning, verbal working memory, processing
speed, inhibition, and attention, have been shown to be consistently impaired in
schizophrenia, and thus domains to monitor for sensitivity to nicotine or smoking effects to
test the self-medication hypothesis of smoking in this disorder (Green et al., 2004;
Westerhausen et al., 2011). To minimize practice effects and novelty of cognitive
assessments, subjects were administered the cognitive battery twice on the same day ~2

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 5

weeks prior to smoking cessation (Goldberg et al., 2010; Lees et al., 2015). Executive
Author Manuscript

control and cognitive inhibition were evaluated with the Stroop Color-Word Test (SCWT)
(Trenerry et al., 1989). Short-term working memory was measured using the Letter Number
Sequencing tasks (LNS) and Digit Span (DS) (Kaplan, 1995; Twamley et al., 2006).
Processing speed was measured using the WAIS-III Digit Symbol Task (DST) and Symbol
Search (SS) tests (Wechsler, 1997). Verbal fluency was measured using the Controlled Oral
Word Association Test (FAS) (Benton et al., 1994). Trail Making Test (TMT) was used to
measure visual tracking (Part A, TMT-A) and executive control (Part B, TMT-B)
(Mitrushina et al., 2005). Immediate and delayed verbal memory were measured using the
Hopkins Verbal Learning Task (HVLT) (Brandt, 1991), and alternative forms were used for
each assessment on this test. Vigilance was measured using the Continuous Performance
Test, Identical Pairs version (CPT-IP) (Cheung et al., 2004) (Tests are further described in
the Supplemental Text and Supplement Table 2). The entire battery took under an hour to
Author Manuscript

administer. The order of tests was consistent throughout and was: HVLT-immediate, DSC,
SS, TMT-A, TMT-B, DS, LNS, FAS, SCWT, CPT-IP and finally HVLT-delayed.

2.2.5 Other Assessments—Positive, negative and general symptoms of psychosis were

measured by the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1989) and the
Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1989). Depressive
symptoms were assessed by the Montgomery-Asberg Depression Scale (MADRS)
(Montgomery, 1979) and involuntary movements by the Abnormal Involuntary Movements
Scale (AIMS) (Guy, 1976a).

2.2.6 Schedule of Assessments—The schedule of assessments is summarized in

Supplementary Figure 1. Cognitive testing was conducted: 1) two weeks prior to smoking
cessation twice to control for practice effects, 2) at baseline (smoking as usual state) within 1
Author Manuscript

hour of smoking, 3) one day after smoking cessation (early abstinence), 4) ~1 week of
smoking abstinence (extended abstinence) and 4) 21 days +/− 3 days (~3 weeks) upon
resumption of smoking within 1 hour of smoking (resumption). Cognitive testing was
performed in the morning. This On-Off-Off-On design provided the opportunity to study the
effects of smoking on cognitive test performance. PANSS, SANS, MADRS and AIMS
testing occurred at baseline while smoking as usual and ~1 week of smoking abstinence
(extended abstinence). Smoking breaks were not permitted during testing.

2.3 Statistical Analysis

Baseline raw scores on cognitive assessments were tested for normality using Shapiro-Wilk
tests. Non-normally distributed data (for DS, LNS, DST, TMT-A, TMT-B, and CPT-IP
number of false alarms and reaction time) were natural log- transformed to achieve a normal
Author Manuscript

distribution of baseline scores. Z-scores were computed with these normally distributed
baseline scores as reference, and used to calculate a global cognitive index (GCI) for each
time point for each participant by averaging z scores of cognitive tests’ results (SI, DS, LNS,
DST, SS, TMT-A, TMT-B, FAS, HVLT immediate). For tests where higher performance
corresponds to lower numbers (SI, TMT-A, and TMT-B), z-scores signs were inverted before
averaging. CPT was excluded in the GCI since 7 participants of 26 (~25%) were missing
baseline data on this task for technical reasons; instead, CPT results were analyzed

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 6

separately. GCI was calculated both including and excluding (HVLT-delayed) to examine
Author Manuscript

the effect of using two measures from the same test (HVLT-immediate and -delayed).

GCI scores were compared over time using linear mixed models with time as a within-
subjects factor. The best-fitting variance-covariance structure was selected based on
information criteria. Post-hoc contrasts with paired t-tests were estimated to interpret
significant main effects of time, comparing each time point to every other. Exploratory
analyses included examining each cognitive measure with the same linear mixed models
with time as a within-subjects factor. Behavioral assessments were compared with paired t-
tests, and Bonferroni corrections were applied for multiple comparisons.

3. RESULTS
3.1 Study Participants
Author Manuscript

A total of 26 subjects (23 male) were enrolled in the study and hospitalized (Supplemental
Figure 2), and their demographic data and baseline behavioral assessments are shown in
Table 1. The subjects had at least moderate dependence for nicotine as assessed by the
FTND. Two subjects were unable to comply with the smoking restrictions and dropped out
during the inpatient phase (one subject on the 1st day and one on the 4th day). Of the
remaining 24 subjects, two subjects reported remaining abstinent after discharge from the
hospital and were therefore not asked to return for cognitive testing and another two subjects
were lost to follow up. The remaining 20 subjects returned for repeat cognitive testing within
~3 weeks of resuming smoking (Supplementary Figure 2). Thus, 20 subjects had cognitive
performance data for all 4 time points. Five subjects were not receiving antipsychotic
treatment, 5 were receiving first generation antipsychotics, and 16 were receiving second-
generation antipsychotics, including one receiving clozapine (Supplementary Table 3:
Author Manuscript

Prescribed Antipsychotics).

3.2 Breath CO and urine cotinine levels

Breath CO and urine cotinine levels fell below levels consistent with smoking abstinence
and remained at those levels during the inpatient hospitalization (Figure 1). Furthermore,
plasma cotinine levels also confirmed abstinence from smoking. Measures of nicotine
withdrawal and urges to smoke increased in early abstinence and decreased after day 2
through the week of abstinence as shown in Supplementary Figure 3.

3.3 Cognitive Test Performance

Results of cognitive testing at each time point and the statistical test results are presented in
Table 2. There was no main effect of time over the period including the assessments during
Author Manuscript

smoking as usual, early abstinence, prolonged abstinence, and resumption of smoking on

overall cognition as measured by the GCI with only immediate HVLT included
(F(3,67)=1.02, p=0.39) or with both immediate and delayed HVLT included (F(3,67)=2.39,
p=0.08). Despite the lack of any statistically significant effects of time, post-hoc
comparisons were done to explore whether there were any possible significant differences
between any two time points for the GCI; there were no significant differences between any

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 7

time points except for the GCI with both HVLT measures between baseline smoking and
Author Manuscript

prolonged abstinence (t=−2.3, p=0.03).

All cognitive tests individually were subject to the same modeling for exploratory purposes.
There was a significant effect of time on one processing speed task, the SS task (F(3,65) =
3.53, p = 0.019), as well as on HVLT-delayed recall (F(3,67) = 4.4, p = 0.007). Post-hoc
testing between time points revealed that test performance was worse during early and
prolonged smoking abstinence relative to both smoking as usual at baseline and after
resumption of smoking. There was no main effect of time for the CPT-IP on any CPT-IP
measure, though the number of misses showed a trend for being negatively affected by
smoking abstinence F(3,49)=2.26, p=0.09. However, when Bonferroni corrections for
multiple comparisons (13) were applied (p < 0.004), there are no main effects of time on any
tests, including the SS task and HVLT-delayed recall.
Author Manuscript

3.4 Psychosis Symptoms and Antipsychotic Side Effects

As reported elsewhere (Esterlis et al., 2014) there were no significant changes between the
baseline smoking-as-usual state and prolonged smoking abstinence in the PANSS total,
positive symptom subscale, or negative symptom subscale scores; SANS total scores;
MADRS total scores; and AIMS total scores (Table 3). The small decrease in PANSS
negative symptoms from baseline to prolonged nicotine abstinence of 0.8 points out of a
total of 49 did not survive adjustment for multiple comparisons.

4. DISCUSSION
This is the first study to our knowledge to study the effects of smoking in the On – Off –
Off- On design in smokers with schizophrenia. Contrary to our hypothesis, neither early nor
Author Manuscript

prolonged abstinence from smoking, nor the resumption of smoking, had a significant effect
on cognitive test performance in 1 pack per day heavy smokers with schizophrenia.
Similarly, there were no effects on the core symptoms of schizophrenia, depression or
dyskinesia. The results of this study are not consistent with the widely held view that
smokers with schizophrenia smoke tobacco to “self-medicate” cognitive deficits or other
symptoms associated with schizophrenia.

4.1 Cognitive Test Performance

Contrary to the study hypothesis, across a broad range of cognitive domains tested,
performance did not decline significantly either 1-day or ~1 week after smoking cessation,
suggesting that smoking abstinence in tobacco dependent smokers with schizophrenia,
(based on self-report, FTND scores, and urine cotinine values) does not substantially worsen
Author Manuscript

cognitive deficits. While performance on the 3 of the 13 measures including the SS, HVLT-
delayed recall, and CPT-IP missed trials, showed worsening with abstinence and
improvement with resumption of smoking, these effects were not significant (CPT-IP missed
trials) or did not survive adjustment for multiple comparisons (SS and HVLT-delayed). We
believe that the weak effects of smoking status we have found are non-specific and unlikely
to be clinically significant. Other verbal working memory tests (LNS, DS, and most notably
HVLT-immediate recall) and speed of processing tests (DSC, TMT-A) did not show this

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 8

pattern of worsening performance with smoking abstinence, further suggesting that smoking
Author Manuscript

status in schizophrenia may not be affecting the performance in these cognitive domains in a
clinically significant manner. It is possible that delayed memory, with delay of 5-up to 60
minutes, is more sensitive to the effects of nicotine than immediate memory in some
individuals with schizophrenia. Similar to our findings, Myers et al found that visuospatial
delayed recognition (5–7 minutes) but not immediate recall was improved in smokers with
schizophrenia by nicotine administration but this may also be an effect of reversing non-
specific acute withdrawal effects, as performance was worse without nicotine in smokers
with schizophrenia versus non-smokers with schizophrenia but improved only in smokers
when nicotine was administered. Attention is often thought to be the domain most improved
with nicotine administration and thus, the lack of any statistically significant effect of
smoking abstinence or resumption on the CPT was surprising especially since some studies
(Barr et al., 2007; Dépatie et al., 2002; Smith et al., 2005) but not others (Boggs et al., 2013;
Author Manuscript

Sherr et al., 2002) showed that in smokers with schizophrenia CPT scores improve with
nicotine administration. Studies of decreased nicotine intake in schizophrenia on CPT,
however, have been mixed: Sacco et al found no effects of smoking abstinence on CPT
(Sacco et al., 2005) whereas AhnAllen et al found patients smoking cigarettes with
drastically decreased nicotine content worsened CPT (AhnAllen et al., 2015). Collectively,
the lack of any statistically significant worsening of performance on a battery of commonly
used and well-validated neuropsychological tests suggests that smoking cessation and
nicotine withdrawal may have limited effects on cognition in schizophrenia.

Below herewith, several potential explanations for the discrepancy between the study
findings and expectations based on the “self-medication” hypothesis are explored. First, was
the level of nicotine dependence or smoking severity in this sample insufficient to have
allowed for the manifestation of abstinence-related impaired cognitive test performance?
Author Manuscript

The subjects were moderate to heavy smokers whose smoking status (20.3 ± 7.4
cigarettes/day and duration of smoking 24.6 ± 12.8 years) and degree of nicotine
dependence (FTND scores of 5.5 ± 2.1) were confirmed by chart review, self-report and
laboratory testing. Additionally, these levels of smoking in schizophrenia are also consistent
with what have been found in other studies (Wing et al., 2011). Second, could subjects have
failed to abstain? Abstinence from smoking was confirmed by both CO monitoring and
urine cotinine assays – subjects were housed on a locked, smoke-free inpatient research unit
and were paid to attain and maintain abstinence. Furthermore, subjects were not permitted
any nicotine supplements or pharmacological treatments to manage smoking abstinence.
Third, could floor effects in cognitive test performance explain the lack of abstinence-
induced impairments? This appears unlikely given that performance was similar to cognitive
test performance reported in other studies (Schretlen et al, 2007). For example, HVLT total
Author Manuscript

immediate recall scores of 19–21 in this study are similar to those seen in other
schizophrenia studies (Schretlen et al., 2007) – with enough room for both declines and
improvements in task performance. Fourth, could practice effects on cognitive test
performance have obscured abstinence-induced worsening? To minimize practice effects
during the periods of abstinence and resumption of smoking, all subjects were trained on the
cognitive test battery on two separate occasions prior to the baseline visit. Fifth, could the
battery have been not sensitive enough to the effects of smoking abstinence? Several of the

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 9

tests e.g., STROOP, CPT, and other assessments of processing speed have been shown to be
Author Manuscript

sensitive to nicotine effects (Barr et al., 2007; Dépatie et al., 2002; Smith et al., 2005).
Moreover, some of the tests in the battery used e.g., HVLT, are also part of the widely used
MATRICS battery developed for evaluating cognitive treatments for schizophrenia (Green et
al., 2004). Perhaps more proximal measures of brain function e.g., P50 gating, might have
detected abstinence-related effects that could not be detected with the cognitive test battery
(Boggs et al., 2014), but if the commonly used measures of cognitive test performance used
in this study failed to detect the effects of abstinence, the clinical relevance of abstinence
effects is questionable. Finally, while possible, could the lack of effects be explained by
selection bias? It is conceivable that the patients who participated in this study were “aware”
of the lack of significant cognitive impairments with abstinence and thus chose to
participate. This seems unlikely since the overwhelming majority resumed smoking almost
immediately after the required abstinence period.
Author Manuscript

4.2 Clinical Symptom Measures

Similar to cognition, neither 1-day nor ~1 week after smoking cessation, was associated with
any worsening in the core symptoms of schizophrenia, depression or dyskinesia. Finally, as
discussed earlier, it is unlikely that the level of nicotine dependence or smoking severity in
this sample prevented the manifestation of abstinence-related impaired cognitive test
performance.

4.3: Implications for the “Self-Medication” Hypothesis

The findings of this study are not consistent with the widely held view that schizophrenia
patients smoke to “self-medicate” core symptoms. The absence of any significant
abstinence-induced worsening of schizophrenia symptoms, depression symptoms, and
Author Manuscript

movement disorders is consistent with the work of Dalack et al (Dalack et al., 1999). The
findings are also consistent with those of Hahn et al, who reported that the subjective or
objective attentional benefits are unlikely to be the primary driving force of tobacco
consumption in schizophrenia (Hahn et al., 2013.) Our results also parallel the minimal
effects of nicotine on cognition in a rodent neurodevelopmental model of schizophrenia
(Berg et al., 2015). As reported elsewhere (D’Souza et al., 2012; Esterlis et al., 2014), the
same subjects whose cognitive data are reported in this paper showed lower β2*-nAChR
availability relative to smokers without schizophrenia, in striking parallel to the behavioral
and imaging studies done by Berg et al., who found that smoking upregulated β2*-nAChR
in both control and illness-model rodents. In both human schizophrenia and the rodent
model, chronic nicotine use does not completely normalize β2*-nAChR receptor availability,
nor does it substantially affect cognition differently in control and disease condition (Berg et
Author Manuscript

al., 2015; Hahn et al., 2013).

One of the inadvertent negative outcomes of perpetuating the “self-medication” hypothesis

is justifying continued smoking and/or discouraging quitting despite the well-characterized
harmful effects of tobacco use (Chambers, 2009). Moreover, it could limit efforts to find
other explanations for the high rates of tobacco smoking in schizophrenia. The “self-
medication” hypothesis has also been applied to other substance misuse (e.g., cannabis and
alcohol) in schizophrenia. The results of this study are also consistent with other controlled

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 10

experimental studies with alcohol (D’Souza et al., 2006), THC (D’Souza et al., 2005),
Author Manuscript

nicotine (Boggs et al., 2013) that failed to demonstrate clear or robust “benefits” on either
positive, negative or cognitive symptoms in schizophrenia; in fact, symptom worsening was
observed with alcohol and THC. Thus, existing experimental evidence does not support the
“self- medication” hypothesis.

Alternatively, alterations in the neural circuits of reward in schizophrenia could predispose

people with schizophrenia to a higher risk of substance abuse including tobacco smoking
(Chambers et al., 2001; Krystal et al., 2006); substance abuse and schizophrenia may share
common neurobiology. Evidence to support this theory is that a rodent neurodevelopmental
model of schizophrenia shows increased nicotine intake and seeking without cognitive
benefit from nicotine (Berg et al., 2014), and that smokers with schizophrenia choose
smoking over other rewards more than control smokers do (Spring et al., 2003). Perhaps
long-term smoking status enhances baseline cognitive function in individuals with
Author Manuscript

schizophrenia (Wing et al., 2011). However, a cohort of non-smoking individuals with

schizophrenia had statistically similar baseline functioning on the same cognitive battery
(Esterlis et al., 2014).

A third possible explanation for the association between smoking and schizophrenia is that
smoking itself could increase the risk of developing schizophrenia. In a large Swedish
cohort, smoking in early adulthood predicted later diagnosis of schizophrenia. Furthermore,
in the same study, monozygotic twins non-concordant for smoking status showed higher
rates of non-affective psychosis in the smoking twins, suggesting smoking increases the risk
for psychosis rather than a shared genetic link between smoking and psychosis (Kendler et
al., 2015)
Author Manuscript

4.4 Strengths and Weaknesses

To our knowledge this is the only controlled study examining the effects of extended
smoking abstinence (~ 1 week) on cognition in smokers with schizophrenia. A major
strength of the study is the On-Off-Off-On design that provides is an ideal experimental
design to study the effects of smoking abstinence and its reversal with smoking resumption.
Another strength is that this was a within subject design, where each subjects served as
his/her control. That subjects were hospitalized on a smoke-free inpatient unit and had
nicotine abstinence confirmed using overlapping procedures and measures is another
strength of the study. Given that practice effects (Goldberg et al., 2010) are known to occur
with repeated administration of cognitive test batteries, training subjects during the
screening period in this study minimized practice effects. The inclusion of a control group of
smokers without schizophrenia who did not abstain from smoking but had the same schedule
Author Manuscript

of cognitive assessments would have been a stronger control for practice effects on the
cognitive battery, which could have been attenuated by abstinence. The assessment of
outcomes relevant to schizophrenia including cognitive measures in multiple domains and
symptoms (e.g., core symptoms (PANSS), depression (MADRS), and movement disorders)
provide a more complete evaluation of possible effects of abstinence. Though the measures
used were broad, other measures, such as measures of neuroplasticity or social functioning,
might be affected in clinically meaningful ways by smoking abstinence, and this should be

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 11

studied in the future. There was also not a dedicated measure of visuospatial working
Author Manuscript

memory in this battery, though many measures depended upon this domain (CPT, SS, DSC).
Additional measures of visuospatial memory would have been instructive as the literature
about nicotine use on visuospatial working memory in smokers with schizophrenia is mixed
(AhnAllen et al., 2015; Sacco et al., 2005). The sample size of this within- subject study was
larger than or comparable to other studies of nicotine effects and/or abstinence in
schizophrenia.

4.5 Conclusions and Future Directions

In this within subjects, On-Off-Off-On designed study, early and prolonged abstinence from
smoking did not significantly impair cognitive test performance on a broad range of tests in
1 pack per day smokers with schizophrenia. Smoking abstinence also did not worsen core
symptoms of schizophrenia, depression or movement disorders.
Author Manuscript

The study results and the growing literature of small of no effects of smoking withdrawal or
prolonged abstinence on core features of schizophrenia (reviewed in Boggs et al 2014)
challenge the widely held self-medication hypothesis of smoking in schizophrenia (Kumari
and Postma, 2005; Leonard et al., 2007; Wing et al., 2012). Alternative hypotheses are worth
pursuing, not only for understanding why people with schizophrenia smoke, but also for
developing effective treatments for schizophrenia, improved strategies for smoking cessation
for patients, and better ways to prevent psychosis. Most importantly, our results in the
context of prior work suggest that the risks of stopping smoking in schizophrenia are small
compared to the known medical risks of continued smoking (Health and Services, 2004) and
provide strong support for clinicians to encourage smoking cessation in schizophrenia.

Supplementary Material
Author Manuscript

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments
The authors wish to acknowledge support from the Department of Veterans Affairs. The authors also thank staff of
the Clinical Neuroscience Research Unit of the Connecticut Mental Health Center in caring for patients while they
were hospitalized to achieve abstinence from smoking, and to staff of the Schizophrenia Neuropharmacology
Research Group at Yale (Maegan Krasenics, Lara Shearer and Michelle Carbuto) for their help in collecting the
data.

FUNDING AND DISCLOSURE

This research was funded by R01 DA-022495 (D.C.D.) and NARSAD (I.E.). Salary support was provided by
K01MH092681 (I.E.), K02DA031750 (K.C.), and VA VISN1 Career Development Award (T.S.S.).
Author Manuscript

References
AhnAllen CG, Bidwell LC, Tidey JW. Cognitive effects of very low nicotine content cigarettes, with
and without nicotine replacement, in smokers with schizophrenia and controls. Nicotine & tobacco
research : official journal of the Society for Research on Nicotine and Tobacco. 2015; 17(5):510–
514. [PubMed: 25143294]
Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Archives of general
psychiatry. 1982; 39(7):784–788. [PubMed: 7165477]

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 12

Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and
theoretical foundations. Br J Psychiatry. 1989; (Suppl 7):49–58.
Author Manuscript

Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, Deckersbach T, Kelly JF,
Freudenreich O, Goff DC. The effects of transdermal nicotine on cognition in nonsmokers with
schizophrenia and nonpsychiatric controls. Neuropsychopharmacology : official publication of the
American College of Neuropsychopharmacology. 2007; 33(3):480–490. [PubMed: 17443126]
Benton AL, Hamsher KD, Sivan AB. Multilingual aphasia examination: manual of instructions. AJA
Assoc. 1994
Berg SA, Sentir AM, Bell RL, Engleman EA, Chambers RA. Nicotine effects in adolescence and
adulthood on cognition and alpha(4)beta(2)-nicotinic receptors in the neonatal ventral hippocampal
lesion rat model of schizophrenia. Psychopharmacology. 2015; 232(10):1681–1692. [PubMed:
25388292]
Berg SA, Sentir AM, Cooley BS, Engleman EA, Chambers RA. Nicotine is more addictive, not more
cognitively therapeutic in a neurodevelopmental model of schizophrenia produced by neonatal
ventral hippocampal lesions. Addiction biology. 2014; 19(6):1020–1031. [PubMed: 23919443]
Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, Cyril D’Souza D. Going up in Smoke? A Review
Author Manuscript

of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia. Current

pharmaceutical design. 2014; 20(31):5077–5092. [PubMed: 24345265]
Boggs DL, Ranganathan M, Sewell RA, Madonick S, D’Souza DC. Pilot study of intravenous nicotine
effects on cognitive performance in schizophrenia. Schizophrenia research. 2013; 150(1):323–324.
[PubMed: 23953216]
Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent
forms. The Clinical neuropsychologist. 1991; 5(2):125–142.
Chambers RA. A Nicotine Challenge to the Self-Medication Hypothesis in a Neurodevelopmental
Animal Model of Schizophrenia. Journal of dual diagnosis. 2009; 5(2):139–148. [PubMed:
20556221]
Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in
schizophrenia. Biological psychiatry. 2001; 50(2):71–83. [PubMed: 11526998]
Cheung AM, Mitsis EM, Halperin JM. The relationship of behavioral inhibition to executive functions
in young adults. Journal of clinical and experimental neuropsychology. 2004; 26(3):393–404.
[PubMed: 15512928]
Author Manuscript

D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R,

Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for
cognition, psychosis, and addiction. Biological psychiatry. 2005; 57(6):594–608. [PubMed:
15780846]
D’Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, Pittman B, Ranganathan M,
Cosgrove K, Staley J. Lower Beta2*-nicotinic acetylcholine receptor availability in smokers with
schizophrenia. The American journal of psychiatry. 2012; 169(3):326–334. [PubMed: 22193533]
D’Souza DC, Gil RB, Madonick S, Perry EB, Forselius-Bielen K, Braley G, Donahue L, Tellioglu T,
Zimolo Z, Gueorguieva R, Krystal JH. Enhanced sensitivity to the euphoric effects of alcohol in
schizophrenia. Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology. 2006; 31(12):2767–2775. [PubMed: 16985503]
Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine withdrawal and
psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology :
official publication of the American College of Neuropsychopharmacology. 1999; 21(2):195–202.
Author Manuscript

[PubMed: 10432467]
Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical
phenomena and laboratory findings. The American journal of psychiatry. 1998; 155(11):1490–
1501. [PubMed: 9812108]
de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between
schizophrenia and tobacco smoking behaviors. Schizophrenia research. 2005; 76(2–3):135–157.
[PubMed: 15949648]
Dépatie L, O’Driscoll GA, Holahan ALV, Atkinson V, Thavundayil JX, Kin N, Lal S. Nicotine and
behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study.

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 13

Neuropsychopharmacology : official publication of the American College of

Neuropsychopharmacology. 2002; 27(6):1056–1070. [PubMed: 12464463]
Author Manuscript

Esterlis I, Ranganathan M, Bois F, Pittman B, Picciotto MR, Shearer L, Anticevic A, Carlson J, Niciu
MJ, Cosgrove KP, D’Souza DC. In vivo evidence for beta2 nicotinic acetylcholine receptor subunit
upregulation in smokers as compared with nonsmokers with schizophrenia. Biological psychiatry.
2014; 76(6):495–502. [PubMed: 24360979]
First, MB., Spitzer, RL., Gibbon, M., Williams, JB. Structured clinical interview for DSM-IV axis I
disorders, clinician version (SCID-CV). Washington, DC: American Psychiatric Association;
1997.
George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, Kosten TR, Wexler BE.
Effects of smoking abstinence on visuospatial working memory function in schizophrenia.
Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology. 2002; 26(1):75–85. [PubMed: 11751034]
Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD. Circumstances under which practice
does not make perfect: a review of the practice effect literature in schizophrenia and its relevance
to clinical treatment studies. Neuropsychopharmacology : official publication of the American
Author Manuscript

College of Neuropsychopharmacology. 2010; 35(5):1053–1062. [PubMed: 20090669]

Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg
TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder
SR. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-
MATRICS conference to select cognitive domains and test criteria. Biological psychiatry. 2004;
56(5):301–307. [PubMed: 15336511]
Guy, W. ECDEU Assessment Manual for Psychopharmacology. Dept. of Health, E.a.W.. , editor.
Washington DC: 1976a.
Guy, W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76–338. US
Department of Health, Education, and Welfare; Washington, D.C.: 1976b.
Hahn B, Harvey AN, Concheiro-Guisan M, Huestis MA, Holcomb HH, Gold JM. A test of the
cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biological psychiatry.
2013; 74(6):436–443. [PubMed: 23660272]
Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B, Zerbe G, Freedman R. Effects
of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology: official publication
Author Manuscript

of the American College of Neuropsychopharmacology. 2004; 29(7):1378. [PubMed: 15138435]

Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, Bierut LJ, Pato MT,
Genomic Psychiatry Cohort C. Comorbidity of severe psychotic disorders with measures of
substance use. JAMA psychiatry. 2014; 71(3):248–254. [PubMed: 24382686]
Health, U.D.o., Services, H.. The health consequences of smoking: a report of the Surgeon General.
Atlanta, GA: 2004.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine
Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British journal of addiction.
1991; 86(9):1119–1127. [PubMed: 1932883]
Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking
on human performance. Psychopharmacology. 2010; 210(4):453–469. [PubMed: 20414766]
Heishman SJ, Snyder FR, Henningfield JE. Performance, subjective, and physiological effects of
nicotine in non-smokers. Drug and alcohol dependence. 1993; 34(1):11–18. [PubMed: 8174498]
Hughes J, Hatsukami D, Mitchell J, Dahlgren L. Prevalence of smoking among psychiatric outpatients.
Author Manuscript

The American journal of psychiatry. 1986; 143:993–997. [PubMed: 3487983]

Kaplan, E. WAIS-R NI: WAIS-R as a Neuropsychological Instrument. Psychological Corporation;
1995.
Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia.
Schizophrenia bulletin. 1987; 13(2):261. [PubMed: 3616518]
Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale
and standardisation. British Journal of Psychiatry – Supplementum. 1989; (7):59–67.

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 14

Kendler KS, Lonn SL, Sundquist J, Sundquist K. Smoking and schizophrenia in population cohorts of
Swedish women and men: a prospective co-relative control study. The American journal of
Author Manuscript

psychiatry. 2015; 172(11):1092–1100. [PubMed: 26046339]

Krystal JH, D’Souza DC, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, Pearlson G. The
vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.
Neurotoxicity research. 2006; 10(3–4):235–252. [PubMed: 17197373]
Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neuroscience &
Biobehavioral Reviews. 2005; 29(6):1021–1034. [PubMed: 15964073]
Lees J, Applegate E, Emsley R, Lewis S, Michalopoulou P, Collier T, Lopez-Lopez C, Kapur S,
Pandina GJ, Drake RJ. Calibration and cross-validation of MCCB and CogState in schizophrenia.
Psychopharmacology. 2015; 232(21–22):3873–3882. [PubMed: 26018529]
Leonard S, Mexal S, Freedman R. Smoking, Genetics and Schizophrenia: Evidence for Self
Medication. Journal of dual diagnosis. 2007; 3(3–4):43–59. [PubMed: 19122786]
Mendrek A, Monterosso J, Simon SL, Jarvik M, Brody A, Olmstead R, Domier CP, Cohen MS, Ernst
M, London ED. Working memory in cigarette smokers: comparison to non-smokers and effects of
abstinence. Addictive behaviors. 2006; 31(5):833–844. [PubMed: 16009504]
Author Manuscript

Mitrushina, M., Boone, K., Razani, J., D’Elia, L. Handbook of normative data for neuropsychological
assessment. 2nd. Oxford University Press; 2005.
Montgomery SM. Depressive symptoms in acute schizophrenia. Prog Neuropsychopharmacol. 1979;
3(4):429–433. [PubMed: 400999]
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese
FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman
LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus
Cognitive Battery, part 1: test selection, reliability, and validity. The American journal of
psychiatry. 2008; 165(2):203–213. [PubMed: 18172019]
Olincy A, Ross RG, Harris JG, Young DA, McAndrews MA, Cawthra E, McRae KA, Sullivan B,
Adler LE, Freedman R. The P50 auditory event-evoked potential in adult attention-deficit disorder:
comparison with schizophrenia. Biological psychiatry. 2000; 47(11):969–977. [PubMed:
10838065]
Patterson F, Jepson C, Loughead J, Perkins K, Strasser AA, Siegel S, Frey J, Gur R, Lerman C.
Working memory deficits predict short-term smoking resumption following brief abstinence. Drug
Author Manuscript

and alcohol dependence. 2010; 106(1):61–64. [PubMed: 19733449]

Roll JM, Higgins ST, Steingard S, McGinley M. Use of monetary reinforcement to reduce the cigarette
smoking of persons with schizophrenia: a feasibility study. Exp Clin Psychopharmacol. 1998; 6(2):
157–161. [PubMed: 9608347]
Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE,
George TP. Effects of cigarette smoking on spatial working memory and attentional deficits in
schizophrenia: involvement of nicotinic receptor mechanisms. Archives of general psychiatry.
2005; 62(6):649–659. [PubMed: 15939842]
Schretlen DJ, Cascella NG, Meyer SM, Kingery LR, Testa SM, Munro CA, Pulver AE, Rivkin P, Rao
VA, Diaz-Asper CM, Dickerson FB, Yolken RH, Pearlson GD. Neuropsychological functioning in
bipolar disorder and schizophrenia. Biological psychiatry. 2007; 62(2):179–186. [PubMed:
17161829]
Sherr JD, Myers C, Avila MT, Elliott A, Blaxton TA, Thaker GK. The effects of nicotine on specific
eye tracking measures in schizophrenia. Biological psychiatry. 2002; 52(7):721–728. [PubMed:
Author Manuscript

12372663]
Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, Sershen H, Li C, Ren J, Liu Y, Youseff M,
Lajtha A, Guidotti A, Weiser M, Davis JM. Varenicline Effects on Smoking, Cognition, and
Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. PloS one. 2016;
11(1):e0143490. [PubMed: 26730716]
Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal
spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology :
official publication of the American College of Neuropsychopharmacology. 2002; 27(3):479–497.
[PubMed: 12225705]

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 15

Smith RC, Warner-Cohen J, Matute M, Butler E, Kelly E, Vaidhyanathaswamy S, Khan A. Effects of

nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology : official
Author Manuscript

publication of the American College of Neuropsychopharmacology. 2005; 31(3):637–643.

Smucny J, Olincy A, Rojas DC, Tregellas JR. Neuronal effects of nicotine during auditory selective
attention in schizophrenia. Human brain mapping. 2016; 37(1):410–421. [PubMed: 26518728]
Spring B, Pingitore R, McChargue DE. Reward value of cigarette smoking for comparably heavy
smoking schizophrenic, depressed, and nonpatient smokers. The American journal of psychiatry.
2003; 160(2):316–322. [PubMed: 12562579]
Tidey JW, Higgins ST, Bickel WK, Steingard S. Effects of response requirement and the availability of
an alternative reinforcer on cigarette smoking by schizophrenics. Psychopharmacology. 1999;
145(1):52–60. [PubMed: 10445372]
Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and
bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology. 2011;
217(2):279–287. [PubMed: 21475970]
Trenerry, M., Crosson, B., DeBoe, J., Leber, W. Psychological Assessment Resources. 1989. Stroop
Neuropsychological Screening Test.
Author Manuscript

Twamley EW, Palmer BW, Jeste DV, Taylor MJ, Heaton RK. Transient and executive function working
memory in schizophrenia. Schizophrenia research. 2006; 87(1–3):185–190. [PubMed: 16737800]
Wechsler, D. WAIS-III: Wechsler adult intelligence scale. Psychological Corporation; San Antonio,
TX: 1997.
Westerhausen R, Kompus K, Hugdahl K. Impaired cognitive inhibition in schizophrenia: a meta-
analysis of the Stroop interference effect. Schizophrenia research. 2011; 133(1–3):172–181.
[PubMed: 21937199]
Wing VC, Bacher I, Sacco KA, George TP. Neuropsychological performance in patients with
schizophrenia and controls as a function of cigarette smoking status. Psychiatry research. 2011;
188(3):320–326. [PubMed: 21669462]
Wing VC, Wass CE, Soh DW, George TP. A review of neurobiological vulnerability factors and
treatment implications for comorbid tobacco dependence in schizophrenia. Annals of the New
York Academy of Sciences. 2012; 1248:89–106. [PubMed: 22129082]
Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP. Nicotine decreases bradykinesia-rigidity in
Author Manuscript

haloperidol-treated patients with schizophrenia. Neuropsychopharmacology : official publication

of the American College of Neuropsychopharmacology. 2002; 27(4):684–686. [PubMed:
12377405]
Yee A, Bt Nek Mohamed NN, Binti Hashim AH, Loh HS, Harbajan Singh MK, Ng CG, Jambunathan
ST. The effect of nicotine dependence on psychopathology in patients with schizophrenia. BioMed
research international. 2015; 2015:730291. [PubMed: 26060820]
Author Manuscript

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 16
Author Manuscript
Author Manuscript

Figure 1. Measures of Smoking Abstinence

Expired carbon monoxide (CO) (top graph) and urine cotinine (bottom graph) were
Author Manuscript

collected at baseline and daily during inpatient hospitalization to ensure that subjects
continued to abstain from smoking cigarettes during the entire study period.
Author Manuscript

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Boggs et al. Page 17

Table 1

Sample Characteristics (n=26)

Author Manuscript

Variables Mean SD
Age 41.7 11.9

Years smoking 24.6 12.8

Cigarettes per day 20.3 7.4

Age of diagnosis 23.9 7.5

Years diagnosed 17.3 10.6

Fagerström Test for Nicotine Dependence 5.5 2.1

Minnesota Nicotine Withdrawal Questionnaire 8.3 6.1

Tiffany Questionnaire of Smoking Urges desire 34.6 13.4

Tiffany Questionnaire of Smoking Urges relief 32.1 10.8

Positive and Negative Syndrome Scale (PANSS) – positive 19.1 4.1

Author Manuscript

Positive and Negative Syndrome Scale (PANSS) – negative 19.2 5.3

Positive and Negative Syndrome Scale (PANSS) – total 73.1 10.0

Scale for the Assessment of Negative Symptoms (SANS) 29.4 15.5

Montgomery-Asberg Depression Rating Scale (MADRS) 7.2 6.7

Abnormal Involuntary Movement Scale (AIMS) 1.7 2.6

Author Manuscript
Author Manuscript

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

 Author Manuscript Author Manuscript Author Manuscript Author Manuscript

TABLE 2

COGNITIVE TEST PERFORMANCE OVER TIME

COGNITIVE TASKS Baseline: Smoking as Immediate Abstinence Extended Smoking Resumption of Smoking Effect over time Post hoc comparisons
Usual (12–24 hours after Abstinence
Boggs et al.

(~21 days)d
(Day #1)a quitting)b (~day 7)c

Global cognitive index 0 (0.641) −0.06 (0.585) −0.05 (0.682) 0.04 (0.676) F(3,67)= 1.02,
p = 0.390

SCWT interference score* 3.68 (8.49) 3.43 (6.07) 3.11 (7.58) 5.71 (7.38) F(3,58)= 0.52,
p = 0.667
WAIS-iii DS score 8.58 (3.11) 8.81 (3.21) 8.63 (3.39) 8.50 (3.02) F(3,67)= 0.58,
p = 0.630
WAIS-iii LNS 8.35 (3.58) 8.15 (3.45) 8.00 (3.55) 8.50 (3.36) F(3,67)= 0.44,
p = 0.723
WAIS-iii DST 6.92 (2.67) 6.73 (2.65) 6.68 (3.00) 7.05 (2.70) F(3,65)= 1.03,
p = 0.387
WAIS-iii SS 7.31 (3.18) 6.65 (2.58) 6.86 (2.82) 7.90 (3.37) F(3,65)= 3.53, d > b (p = 0.004)
p = 0.019 d > c (p = 0.013)

COWAT (FAS) 35.65 (12.26) 33.27 (12.45) 34.08 (11.49) 36.25 (11.28) F(3,67) = 1.32,
p = 0.277
Trails a (sec) 35.65 (18.89) 34.12 (14.57) 32.05 (18.52) 31.75 (12.30) F(3,64)= 0.83,
p = 0.480
Trails b (sec) 114.77 (83.05) 103.00 (59.92) 102.30 (59.62) 98.79 (84.91) F(3,25)= 0.90,
p = 0.454
HVLT total immediate 21.42 (5.78) 19.31 (5.81) 19.79 (4.86) 20.15 (6.27) F(3,67)= 1.67,
p = 0.182
HVLT total delayed 5.42 (2.83) 3.85 (3.09) 4.13 (2.97) 5.35 (2.89) F(3,67)=4.4 a > b (p =0.005)
p = 0.007 a > c (p =0.025)
d > b (p =0.008)

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

d > c (p =0.031)

CPT (IP) missed 13.74 (8.05) 16.37 (7.53) 18.89 (9.00) 16.56 (9.62) F(3,49)= 2.26,
p = 0.093
CPT (IP) false alarms 14.63 (15.22) 14.63 (14.47) 17 (19.10) 18.94 (19.77) F(3,49)= 0.54,
p = 0.658
CPT (IP) reaction time (msec) 828 (157) 850 (156) 817 (138) 807 (118) F(3,48)= 0.36
p = 0.784

CPT = Continuous Performance Task, HVLT = Hopkins Verbal Learning Task, SCWT= Stroop Color-Word Test, WAIS-iii = the Wechsler Adult Intelligence Scale-iii, WAIS-iii DS = WAIS-iii Digit Span,
WAIS-iii LNS = WAIS Letter Number Sequencing, WAIS-iii DST = WAIS-iii Digit Symbol Task, WAIS-iii SS = WAIS-iii Symbol Search, COWAT = Controlled Oral Word Association Test, HVLT =
Hopkins Verbal Learning Test, CPT (IP) = Continuous Performance Test (Identical Pairs)
Page 18
 Author Manuscript Author Manuscript Author Manuscript Author Manuscript
*
Three participants were colorblind, so they did not ever participante in the SCWT, and their CGIs at all 4 time points did not include SCWT.
Boggs et al.

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

Page 19
 Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Table 3

Change in Behavioral and Motor Assessments from Smoking as Usual to Prolonged Smoking Abstinence

Variable N Mean Std Dev Std Error DF t Value Pr > |t|

Boggs et al.

PANSS Total Score 24 1.333 6.041 1.233 23 1.08 0.2908

PANSS Positive Symptoms score 24 0.5 2.621 0.535 23 0.93 0.3597

PANSS Negative Symptoms score 24 −0.792 1.865 0.381 23 −2.08 0.0488

SANS total score 24 1.583 7.689 1.57 23 1.01 0.3236

MADRS total score 24 −0.417 3.866 0.789 23 −0.53 0.6026

AIMS total score 21 0.286 1.419 0.31 20 0.92 0.3672

PANSS = Positive and Negative Syndrome Scale; SANS = Schedule for the Assessment of Negative Symptoms; MADRS = Montgomery Asberg Depression Rating Scale; AIMs = Abnormal Involuntary
Movement Scale

Schizophr Res. Author manuscript; available in PMC 2019 April 01.

Page 20